6.42
-0.25(-3.75%)
Currency In USD
Address
56 Evergreen Drive
Portland, ME 04103
United States of America
Phone
207 878 2770
Website
Sector
Healthcare
Industry
Biotechnology
Employees
69
First IPO Date
May 05, 1987
| Name | Title | Pay | Year Born |
| Michael F. Brigham | Special Advisor to the Chief Executive Officer & Director | 392,609 | 1961 |
| F. Olivier Te Boekhorst | President, CEO & Director | 0 | N/A |
| Bobbi Jo Brockmann | Vice President of Sales & Marketing and Director | 364,403 | 1977 |
| A. Gustavo Scaffa | Senior Director of Quality | 0 | N/A |
| Timothy C. Fiori | Chief Financial Officer, Secretary, Treasurer & Director | 0 | 1979 |
| Elizabeth S. Toothaker | Director of Finance & Administration and Controller | 0 | N/A |
| John W. Zinckgraf | Director of Product Development | 0 | N/A |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.